ArticleInvestigative ophthalmology & visual science2009
Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis.
Article in Investigative ophthalmology & visual science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Cytokines and chemokines involved in HLA-B27-positive ankylosing spondylitis-associated acute anterior uveitis.Molecular vision · 2023Article
- Activated Hepatic Stellate Cells (HSCs) Exert Immunosuppressive Effects in Hepatocellular Carcinoma by Producing Complement C3.OncoTargets and therapy · 2020Article
- CD55 Is Essential for CD103The American journal of pathology · 2019Article
- Complement-Mediated Activation of the NLRP3 Inflammasome and Its Inhibition by AAV-Mediated Delivery of CD59 in a Model of Uveitis.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Doyne lecture 2016: intraocular health and the many faces of inflammation.Eye (London, England) · 2017Review
- Complement Component C4 Regulates the Development of Experimental Autoimmune Uveitis through a T Cell-Intrinsic Mechanism.Frontiers in immunology · 2017Article
- Targeting the complement system for the management of retinal inflammatory and degenerative diseases.European journal of pharmacology · 2016Review
- Painting factor H onto mesenchymal stem cells protects the cells from complement- and neutrophil-mediated damage.Biomaterials · 2016Article
- Complement anaphylatoxin receptors C3aR and C5aR are required in the pathogenesis of experimental autoimmune uveitis.Journal of leukocyte biology · 2016Article
- Autoimmune and autoinflammatory mechanisms in uveitis.Seminars in immunopathology · 2014Review
- Decay-accelerating factor 1 deficiency exacerbates leptospiral-induced murine chronic nephritis and renal fibrosis.PloS one · 2014Article
- The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells.Blood · 2013Article
- Myeloid suppressor cells induced by retinal pigment epithelial cells inhibit autoreactive T-cell responses that lead to experimental autoimmune uveitis.Investigative ophthalmology & visual science · 2012Article
- Inhibition of complement alternative pathway suppresses experimental autoimmune anterior uveitis by modulating T cell responses.The Journal of biological chemistry · 2011Article
- Dynamic control of the complement system by modulated expression of regulatory proteins.Laboratory investigation; a journal of technical methods and pathology · 2011Review
- Complement gene expression and regulation in mouse retina and retinal pigment epithelium/choroid.Molecular vision · 2011Article
- Emerging role of antioxidants in the protection of uveitis complications.Current medicinal chemistry · 2011Review
- Decay accelerating factor (CD55)-mediated attenuation of complement: therapeutic implications for age-related macular degeneration.Investigative ophthalmology & visual science · 2010Article
- Decay-accelerating factor 1 (Daf1) deficiency exacerbates xenobiotic-induced autoimmunity.Immunology · 2010Article
- Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.Clinical and experimental immunology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeTo investigate the role of decay-accelerating factor (DAF), a cell surface complement regulator that recently has been linked to T-cell responses and autoimmunity in the pathogenesis of experimental autoimmune uveitis (EAU).
methodsEAU was induced in wild-type (WT) and Daf1(-/-) mice, and their disease severities, IRBP specific Th1/Th17 responses, and cytokine expression profiles were compared. In a test of the efficacy of treatment with soluble mouse DAF protein, EAU was induced in disease-susceptible B10.RIII mice, and they were treated with 0.5 mg soluble DAF protein or equal volume of PBS IP every other day. Retinal histology and IRBP-specific T-cell responses were compared after 14 days.
resultsBoth EAU incidence and histopathology scores were significantly greater in Daf1(-/-) mice. There was a >10-fold greater mononuclear cell influx into the retina together with severe vasculitic lesions, retinal folding, and photoreceptor cell layer destruction. There were 5- to 7-fold greater Th1 and 3- to 4-fold greater Th17 responses against IRBP in Daf1(-/-) mice with EAU, and they expressed significantly elevated levels of GM-CSF, IL-2, IL-3, and IFN-gamma. WT B10.RIII mice that received soluble DAF protein treatments exhibited decreased IRBP-specific Th1/Th17 responses and were protected from retinal injury compared with the mice that received PBS treatments.
conclusionsDAF significantly influences IRBP-specific Th1 and Th17 responses and disease severity in EAU. Systemic upregulation of DAF levels could be used to suppress retinal antigen(s)-specific autoimmunity to treat autoimmune posterior uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.